VRX-496 VIRxSYS

Current Opinion in Investigational Drugs

Volumn 6, Issue 2, 2005, Pages 209-215

  Morris, Kevin V ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; VRX 496; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG SYNTHESIS; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS RECOMBINATION; VIRUS REPLICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; SYNTHESIS;

AIDS VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HIV INFECTIONS; HIV-1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15744375372     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. A controlled, phase I clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Wong Staal F, Poeschla EM, Looney DJ HUM GENE THER 1998 9 16 2407-2425
2. Optimization of HIV-based vectors with anti-HIV antisense envelope sequences for AIDS gene therapy. Lu X, Yu Q, Slepushkina T, Merling R, Slepushkin CV, Conde B, Li Y, Chang YN, Dropulic B MOL THER 2001 3 5 Pt 2 Abs 405
3. Optimization of HIV vectors expressing anti-HIV antisense for AIDS gene therapy. Dropulic B, Lu X, Slepushkin V, Han W, Humeau L, Yu Q, Davis B, Li Y, Conde B, Ni Y, Carroll R et al MOL THER 2001 3 5 PT 2 Abs 42
4. American Society of Gene Therapy - Fourth Annual Meeting (Part II) - OVERNIGHT REPORT, Seattle, WA, USA. McGowran M IDDB MEETING REPORT 2001 May 30-June 03
5. Inhibition of HIV-1 replication by an HIV-1 based vector that expresses a triple anti-HIV tat ribozyme cassette. Yu Q, Lu X, Slepushkin V, Chang YN, Dropulic B MOL THER 2001 3 5 Pt 2 Abs 1048
6. High transduction efficiency of primary human CD4+ T-cells and potent inhibitors of wt-HIV replication by an HIV vector containing an anti-HIV antisense payload. Humeau L, Merling R, Li Y, Lu X, Slepushkin V, Chang YN, Man W, Carroll R, June C, Dropulic B MOL THER 2001 3 5 Pt 2 Abs 1050
7. VirxSys lentivirus IND for HIV will be filed by first quarter of 2002. FDC REPORTS PINK SHEET 2001 63 47 18-19
8. Suppression of HIV replication and restoration of patient CD4 T cell function by lentivector mediated anti-HIV gene transfer. Han W, Dropulic L, Lesher M, Humeau L, Merling R, Lu X, Slepushkin V, Li Y, Conde B, Schonely K, Chang YN, Dropulic B BLOOD 2001 98 11 Suppl 1 Abs 2093
9. Pre-clinical optimization of HIV vectors expressing anti-HIV antisense for phase I clinical trials in HIV-infected patients. Dropulic B, Lu X, Slepushkin V, Han W, Humeau L, Li W, Levine B, Conde B, Yu Q, Ni Y, Davis BM, Carroll R BLOOD 2001 98 11 Suppl 2 Abs 5426
10. Suppression of HIV replication and selective survival of CD4 cells modified with an HIV-1 based vector expressing an anti-HIV antisense sequence after HIV-1 infection. Han W, Dropulic L, Lesher M, Humeau L, Merling R, Lu X, Slepushkin V, Li Y, Conde B, Schonely K, Chang YN, Dropulic B MOL THER 2002 5 5 Abs 541
11. Pre-clinical optimization of HIV vectors expressing anti-HIV antisense sequences for phase I clinical trials in HIV-infected patients. Dropulic B, Humeau L, Lu X, Slepushkin V, Li Y, Conde B, Yu Q, Ni Y, Davis B, Carrol R et al MOL THER 2002 5 5 Abs 542
12. High transduction efficiency of primary human CD4+ T cells and potent inhibition of wt-HIV replication by an HIV vector containing an anti-HIV antisense payload. Humeau L, Merling R, Li Y, Lu X, Slepushkin V, Chang YN, Han W, Carroll R, June C, Dropulic B MOL THER 2002 5 5 Abs 543
13. HIV-1 resistance to an anti-HIV antisense payload in HIV-1 based vectors results in HIV genomes that are severely attenuated for replication. Yu Q, Lu X, Chen Z, Chang YN, Dropulic B MOL THER 2002 5 5 Abs 544
14. Drug development pipeline: VRX-496. VIRxSYS Corp COMPANY COMMUNICATION 2002 September 17
15. Transduction of CD34+ hematopoietic progenitor cells with a lentiviral vector expressing antisense HIV-1 env sequences protects CD4+ T cell progeny from SHIV infection. Braun SE, Wong FE, Connole M, Lee L, Drouplic B, Johnson RP BLOOD 2002 100 11 Abs 2561
16. VIRxSYS to start VRX-496 clinical trials. VIRxSYS Corp PRESS RELEASE 2003 February 14
17. Biological therapy of HIV/AIDS using HIV-based vectors containing anti-HIV genetic payloads. Dropulic B, Humeau L, Lu X, Slepushkin V, Levine B, Yu Q, Ni Y, Davis B, Carroll R, Chang Y, June C INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2003 10 Abs 140
18. VIRxSYS treats first patient in VRX-496 HIV/AIDS trial. VIRxSYS Corp PRESS RELEASE 2003 July 31
19. Clinical protocol: A phase I open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. MacGregor RR HUM GENE THER 2001 12 16 2028-2029
20. High transduction efficiency of primary human CD4+ T cells and potent inhibition of wt-HIV replication by a safe LTR driven HIV vector containing an anti-HIV antisense payload. Humeau L, Merling R, Li Y, Lu X, Slepushkin V, Chang Y, Han W, Carroll R, June C, Dropulic B BLOOD 2001 98 11 Pt 2 410b
21. Selection for human peripheral blood CD34 cells, CD4 lymphocytes and mouse hematopoietic progenitors transduced with a therapeutic lentiviral vector expressing P140K MGMT and an antisense-HIV env sequence. Davis BM, Han W, Lu X, Chang YN, Dropulic B BLOOD 2001 9811 Pt 1 213a
22. Safety board supports continuation of VIRxSYS's HIV trial. VIRxSYS Corp PRESS RELEASE 2003 September 04
23. Cell & Gene Therapies - SMi Conference, London, UK. Aird J IDDB MEETING REPORT 2003 September 24-25
24. Lentiviral vectors in the clinic - gene therapy for AIDS using HIV-based lentiviral vectors. Dropholic B SMI CONF- CELL GENE THERAPIES 2003 24-25 September
25. DSMB recommends continuation of VIRxSYS's phase I HIV trial. VIRxSYS Corp PRESS RELEASE 2004 April 05
26. Ribozymes in gene therapy of HIV-1. Macpherson JL, Ely JA, Sun LQ, Symonds GP FRONTIERS BIOSCI 1999 4 D497-D505
27. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. Lu X, Yu Q, Binder GK, Chen Z, Slepushkina T, Rossi J, Dropulic B J VIROL 2004 78 13 7079-7088
28. Safe two-plasmid production for the first clinical lentivirus vector that achieves > 99% transduction in primary cells using a one-step protocol. Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T, Chen Z, Merling R, Davis B, Chang YN, Dropulic B J GENE MED 2004 6 9 963-973
29. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, Pereira M, Slepushkina T, Barnett S, Dropulic LK, Carroll R et al MOL THER 2004 9 6 902-913
30. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuscht T NATURE 2001 24 411 428-429.
31. Human immunodeficiency virus type 1 escape from RNA interference. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B J Virol 2003 7721 11531-11535.
32. Drug resistance mutations in HIV-1. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD HIV MED 2003 11 3 92-96
33. HIV-2 and SIV vector systems. Gilbert JR, Wong-Staal F SOMATIC CELL MOL GENET 2001 26 1-6 83-98
34. Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Hamada M, Ohtsuka T, Kawaida R, Koizumi M, Morita K, Furukawa H, Imanishi T, Miyagishi M, Taira K ANTISENSE NUCLEIC ACID DRUG DEV 12 5 301-309
35. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Kawasaki H, Taira K NATURE 2004 431 7005 211-217
36. Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Leavitt MC, Yu M, Yamada O, Kraus G, Looney D, Poeschla E, Wong-Staal F HUM GENE THER 1994 5 9 1115-1120
37. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J NATBIOTECHNOL 2002 20 5 500-505
38. Once-a-day HAART: Dream or reality? Maggiolo F, Ripamonti D, Suter F HIV CLIN TRIALS 2003 4 3 193-201
39. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T CELL 2002 110 5 563-574
40. Lentiviral vectors for gene therapy of HIV-1 infection. Mautino MR CURR GEN THER 2002 2 1 23-43
41. Small interfering RNA-induced transcriptional gene silencing in human cells. Morris KV, Chan SW, Jacobsen SE, Looney DJ SCIENCE 2004 30556881289-1292
42. Transduction of cell lines and primary cells by FIV-packaged HIV vectors. Morris KV, Gilbert J, Wong-Staal F, Gasmi M, Looney DJ MOL THER 2004 101 181-190
43. Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection. Morris KV, Rossi JJ CURR HIV RES 2 2 185-191
44. Ribozyme therapy for HIV infection. Rossi JJ ADV DRUG DELIV REV 2000 441 71-78
45. Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Williams BR BIOCHEM SOC TRANS 1997 25 2 509-513
46. Development of an efficient small interfering RNA (siRNA) expression system with a lentiviral vector. Sumimoto H, Miyagishi M, Miyoshi H, Taira K, Kawakami Y MOL THER 2003 7 5 S34
47. Transcription start regions in the human genome are favored targets for MLV integration. Wu X, Li Y, Crise B, Burgess SM SCIENCE 2003 300 5626 1749-1751
48. Development of lentiviral vectors for gene therapy for human diseases. Buchschacher GL Jr, Wong-Staal F BLOOD 2000 95 8 2499-2504
49. 20 Years since human immunodeficiency virus discovery: Considerations for the next decade. Idemyor V PHARMACOTHERAPY 2003 23 3 384-387
50. The HIV-1 vaccine race. Ho DD, Huang Y CELL 2002 110 2 135-138
51. Drug resistance mutations in HIV-1. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD TOPICS HIV MED 2003 11 3 92-96